Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Laura Mezzalira

University of Ferrara, Italy

Title: Phototherapy at home for the treatment of neonatal jaundice: An innovative, patient-centered pilot project during the COVID-19 pandemic

Biography

Biography: Laura Mezzalira

Abstract

Introduction. Approximately 60% of term babies develop jaundice. This often requires inpatient hospital treatment with phototherapy. Home phototherapy is not well-established within Italy as routine care for the management of neonatal jaundice. The 2019 outbreak of the coronavirus disease has changed hospitals' policies around perinatal care, banning fathers and extra people from entering the neonatal ward to keep mothers and babies safe. The prolonging hospital stay for phototherapy would increase by the stress of isolation, making lockdown in hospital challenging for maternal mental health and breastfeeding initiation. The purpose of this study is to report a patient-centered pilot project of phototherapy at home during the COVID-19 pandemic, to promote mother and baby bonding and experience of neonatal jaundice by reducing hospital stay.

 

Methods: newborn babies were considered for home phototherapy during the COVID-19 outbreak following the guideline (‘Home Phototherapy’: ST-MD-01, 03.15.2018, Policlinico Abano Terme). Inclusion criteria: feeding established, bilirubin levels at >75 <90 percentile (Bhutani nomogram), weight loss <10%, parents motivated, no social concerns, and lived within a pre-defined surrounding area (the Euganean Hills). The equipment used for phototherapy at home is Mira®, GINEVRI srl. Albano Laziale, Rome. The baby was visited 24 hours after hospital discharge        

 

Results: 21 babies were included between January and May 2021. Mean gestational age was 39.73 ± 1.13 weeks, average weight 3,355.90 ±419 g, average discharged home day 2.3±04, and average days received phototherapy at home 1.27±0.43. No adverse events were noted. Two additional babies could be included but they did not live within the pre-defined area. Conclusion: The pilot project of ‘Home Phototherapy’ was well appreciated by parents and cost-effective to improve maternal and newborn health. It has given us the basis to roll this project out to different Level 1–3 neonatal units across the country after the Covid-19 outbreak.